At 8.2x earnings and just 5x forward earnings, the market is clearly pricing RM as a distressed or no-growth lender despite a 0.3 forward PEG that implies sharp earnings acceleration relative to valuation. The sub-1.0 Price/Book of 0.9 and Price/Sales of 0.7 reinforce the deep value profile, but the Altman Z-Score of 1.1 is flashing balance sheet stress, keeping this firmly in the “statistically cheap for a reason” bucket. With a $341M market cap, 8.50% ROE, and 6.30% ROIC, this is not a high-quality compounder — it’s a leveraged credit play where survival and credit performance dictate upside. The market is discounting real financial risk, but if forward EPS of $4.71 materializes, the 5x forward multiple is extremely mispriced relative to growth expectations. This is a classic high-risk, high-reward deep value setup rather than a safe GARP compounder.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.